Tackling one of biopharma's top policy concerns, the leaders of the Senate Judiciary Committee's Intellectual Property Subcommittee are working on legislation to revise the standard for determining what inventions are eligible to be patented.
"Everyone knows the current standard is a mess and that is creating massive uncertainty for almost every single industry that relies on patent protections," Subcommittee Chairman Thom Tillis, R-NC, said at a March 13 hearing on oversight of the US Patent and Trademark Office
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?